Real World Experience of a Biodegradable Polymer Sirolimus-Eluting Stent (Yukon Choice PC Elite) in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty: A Multicentric Observational Study (The Elite India Study)
| Autor: | Amrita Singh, Bhupendra Verma, Akhilesh Kumar Patel, Vivek Singh, Deepak Katyal, Pratap Nagarkoti, Manu Kumar, Avinash Singh |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Stent thrombosis medicine.medical_treatment Population lcsh:Medicine 030209 endocrinology & metabolism BPDES Percutaneous coronary intervention STEMI 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Medicine 030212 general & internal medicine Myocardial infarction cardiovascular diseases education Adverse effect Drug-eluting stents education.field_of_study business.industry lcsh:R Stent General Medicine Clinical Science medicine.disease Thrombosis Surgery Deliverability Observational study business Third generation stents |
| Zdroj: | Open Access Macedonian Journal of Medical Sciences Open Access Macedonian Journal of Medical Sciences; Vol 7 No 7 (2019): Apr 15 (OAMJMS); 1103-1109 Open Access Macedonian Journal of Medical Sciences, Vol 7, Iss 7 (2019) |
| ISSN: | 1857-9655 |
| Popis: | BACKGROUND: The durable polymer drug-eluting stents (DPDES) reduce the risk of repeated target vessel revascularisation (TLR) compared with BMS, but are associated with increased risk of late adverse events. In broadly inclusive populations, the biodegradable-polymer drug-eluting stents (BPDES) have favourable results compared with DPDES in the long term. However, its use in primary angioplasty has not been adequately studied, and data of real-world clinical experience is lacking. AIM: Aim of this study was to assess the safety and efficacy of Yukon Choice PC Elite sirolimus-eluting stent (a novel BPDES) in STEMI patients undergoing primary angioplasty. METHODS: We have presented here one-year clinical follow-up data of the Yukon Choice PC Elite sirolimus-eluting stent in patients undergoing primary angioplasty. A total of 636 patients were enrolled in this single arm, prospective observational study from five centres. RESULTS: This multicentric observational study showed excellent safety and efficacy profile of the novel device at one year follow up. The device-oriented composite endpoint (DOCE) of cardiac death, target-vessel reinfarction, and target-lesion revascularisation (TLR) was 2.7%, and the patient-oriented composite endpoint (POCE) of all-cause death, any myocardial infarction, and any revascularisation was 4.2% at one year. Definite or probable stent thrombosis rate was 0.6%, and no events were recorded beyond 6 months of follow up. CONCLUSIONS: In patients with STEMI undergoing primary angioplasty, the use of Yukon Choice PC Elite (biodegradable polymer sirolimus-eluting stent) has excellent results at one year. It, therefore, represents an attractive alternative to second generation DES in this high-risk population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|